Skip to Content

Novo Nordisk A/S ADR NVO Stock Quote

| Rating as of


Last close prices updated as of Feb 06, 2023, 4:59 PM EST | USD | BATS BZX Real-Time Price
  • Last Close 136.79
  • Sector Healthcare
  • Industry Biotechnology
  • Investment Style Large Growth
  • Day Range 136.96  –  138.83
  • Year Range 94.75  –  144.78
  • Market Cap 310.4322 Bil
  • Volume / Avg 1.7 Mil /  1.4 Mil
  • Price / Sales 11.99
  • Price / Book 25.14
  • Forward Div Yield 1.17%
  • Trailing Div Yield 1.16%

Morningstar‘s Stock Analysis NVO

Currency in
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price


5-Star Price


Economic Moat


Capital Allocation


Novo Nordisk Shares Look Slightly Overvalued Following 2022 Results

Karen Andersen Sector Strategist

Analyst Note

| Karen Andersen |

While Novo Nordisk’s 2022 top- and bottom-line performance met our expectations, the massive demand for the firm’s GLP-1 products in both diabetes and obesity has led to ongoing supply issues. We’ve significantly raised our capital expenditure assumptions as Novo Nordisk moves aggressively to expand supply for current and future products. We’ve slightly lowered our 2023 forecast to account for a reversal to foreign exchange headwinds and supply issues, although we now think long-term GLP-1 demand could be slightly higher than what we had previously modeled, based on strong sales for obesity drug Wegovy with the return of all dose levels to the U.S. market in December.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics NVO

Company Profile NVO

Business Description

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Novo Alle 1
Bagsvaerd, DK-2880, DNK
Industry Biotechnology
Employees 54,393

Related Articles NVO

FAQs for Novo Nordisk A/S ADR Stock

Yes. NVO has a forward dividend yield of 1.17%. See NVO’s full dividends and stock split history on the Dividend tab.
Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.

Learn more about dividend yield.

NVO’s market cap is 310.43 Bil.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares. It’s often used to measure a company’s size. In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.

Learn more about market capitalization.

NVO’s stock style is Large Growth.
Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated.

High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends.

Learn more about style.

NVO’s price/sales is 11.99.
Price/sales represents the amount an investor is willing to pay for a dollar generated from a particular company’s sales or revenues.

NVO’s price/forward earnings is 30.58.
Forward P/E gives some indication of how cheap or expensive a stock is compared with consensus earnings estimates. The lower the Forward P/E, the cheaper the stock.

NVO’s price/book is 25.14.
Price/book ratio can tell investors approximately how much they’re paying for a company’s assets, based on historical, rather than current, valuations. Historical valuations generally do not reflect a company’s current market value. Value investors frequently look for companies that have low price/book ratios.

See NVO’s valuation ratios compared to the Market Index.

NVO’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.

Compare NVO’s historical performance against its industry peers and the overall market.